| 1/30/2026 | BKCVDDEMIGPV | Market Commentary: Team Services prices; market shrugs off Fed nominee; CVR leaks; BioMarin holds premium
|
| 1/30/2026 | HY | Market Commentary: Team Services prices; market shrugs off Fed nominee; CVR leaks; BioMarin holds premium
|
| 1/30/2026 | HY | Market Commentary: Morning Commentary: Junk declines as much as ¼ point as Fed transition rattles markets
|
| 1/29/2026 | BK | Market Commentary: Freeport LNG, Intrado, United, AssetMark, Gibraltar, Flora, ExamWorks, Rehlko and more break
|
| 1/29/2026 | HY | Market Commentary: Primary prices $2.45 billion; AMC improves; CoreWeave dips; funds add $232.7 million
|
| 1/29/2026 | HY | New Issue: BioMarin prices $850 million eight-year notes at par to yield 5½%
|
| 1/29/2026 | HY | BioMarin talks $850 million eight-year notes to yield 5½%-5¾%; books close Thursday
|
| 1/28/2026 | HY | Market Commentary: Velocity prices in dollar market; secondary ‘boring’ post Fed; Ion Platform losses mount
|
| 1/27/2026 | HY | Market Commentary: Euro junk primary active; United Air holds premium; software, health care names pressured
|
| 1/27/2026 | BK | Market Commentary: Nord Anglia, Azuria, BCP Renaissance break; Karman, BioMarin, MKS, Innio updates emerge
|
| 1/27/2026 | CLHY | Market Commentary: Nord Anglia, Azuria, BCP Renaissance break; Karman, BioMarin, MKS updates emerge
|
| 1/27/2026 | BK | BioMarin trims spread on $2 billion term loan B to SOFR plus 175 bps
|
| 1/26/2026 | BKCVDDEMIGPV | Market Commentary: United Airlines drives by; calendar grows; CoreWeave, Applied Digital bounce
|
| 1/26/2026 | HY | Market Commentary: United Airlines drives by; calendar grows; CoreWeave, Applied Digital bounce on Nvidia investment
|
| 1/26/2026 | BKHYIG | S&P gives BioMarin loan BBB-, notes BB
|
| 1/26/2026 | BKHYIG | Fitch gives BioMarin loans BBB-, notes BB+
|
| 1/26/2026 | HY | BioMarin starts roadshow for $850 million eight-year notes; initial talk 5¾%-6%
|
| 1/26/2026 | BKHYIG | Moody's rates BioMarin loans Ba1, notes Ba3
|
| 1/23/2026 | CLHY | Market Commentary: Colonial First, Applied Systems, MacLean Power first-lien term loans free to trade
|
| 1/23/2026 | BK | Market Commentary: Colonial First, Applied Systems, MacLean Power first-lien term loans free to trade
|
| 1/23/2026 | BK | BioMarin readies launch of $2 billion term loan B for Monday
|
| 12/19/2025 | BKHY | BioMarin gets $3.65 billion bridge commitment for Amicus purchase
|
| 9/4/2024 | BK | BioMarin signs new $600 million five-year revolver with Citibank
|
| 8/22/2024 | SP | New Issue: JPMorgan prices $1.43 million return notes linked to basket of 20 stocks
|
| 6/28/2023 | SP | New Issue: JPMorgan prices $1.58 million return notes linked to basket of 20 stocks
|
| 1/26/2023 | CV | Market Commentary: Wolfspeed convertibles in focus, expand post-earnings; BioMarin active; Pinduoduo rises
|
| 10/13/2022 | SP | New Issue: GS Finance sells $1 million digital buffered notes linked to stock basket
|
| 4/29/2022 | SP | New Issue: GS Finance sells $9.25 million basket-linked notes tied to 77 stocks
|
| 8/26/2021 | SP | New Issue: GS Finance prices $13.14 million leveraged basket-linked notes on 179 stocks
|
| 6/2/2021 | BK | BioMarin amends revolver to extend maturity date, lower interest rate
|
| 12/24/2020 | SP | New Issue: Barclays prices $10 million fixed-coupon autocallable securities on BioMarin
|
| 9/28/2020 | SP | New Issue: UBS prices $10 million buffered income autocallables tied to BioMarin
|
| 9/2/2020 | SP | New Issue: Barclays sells $10 million fixed-coupon autocallable notes tied to BioMarin
|
| 8/20/2020 | CV | Market Commentary: Etsy expands; Cinemark gains outright; BioMarin tanks outright, expands dollar-neutral
|
| 5/19/2020 | CV | BioMarin greenshoe lifts 1.25% convertibles to $600 million
|
| 5/12/2020 | CV | Market Commentary: Convertibles primary set to price $2.05 billion in five deals; new notes flood secondary
|
| 5/12/2020 | CVLM | BioMarin may repurchase 1.5% convertibles via new convertibles
|
| 5/12/2020 | CV | New Issue: BioMarin sells upsized $550 million seven-year convertible notes at 1.25%, up 42.5%
|
| 5/11/2020 | CV | Market Commentary: Convertibles primary to price $3.8 billion of notes in five deals; pricing ‘aggressive’
|
| 5/11/2020 | CV | Market Commentary: Morning Commentary: Convertibles primary to price $3.6 billion of notes over five deals
|
| 5/11/2020 | CV | BioMarin to price $500 million seven-year convertible notes to yield 1%-1.5%, up 40%-45%
|
| 5/31/2019 | SP | Goldman amends Cusip for notes tied to basket of Russell 3000 stocks
|
| 5/9/2019 | SP | New Issue: Goldman sells $1 million notes tied to basket of Russell 3000 stocks
|
| 2/25/2019 | CV | Market Commentary: Danaher on tap; BioMarin Pharmaceutical, iQIYI convertible notes active post-earnings; Momo expands
|
| 2/25/2019 | CV | Market Commentary: Morning Commentary: BioMarin Pharmaceutical convertible notes active post-earnings
|
| 2/21/2019 | CV | Market Commentary: Fortive convertibles dominate, expand; Vipshop eyed; BioMarin active pre-earnings
|
| 10/23/2018 | BK | BioMarin gets $200 million three-year revolver with Bank of America
|
| 3/14/2018 | SP | New Issue: Credit Suisse sells $2 million ARES linked to basket of 10 stocks
|
| 3/13/2018 | SP | New Issue: Credit Suisse sells $2.79 million accelerated return notes on 10 stocks
|
| 3/7/2018 | SP | Credit Suisse plans 18-month ARES linked to basket of 10 stocks
|
| 3/7/2018 | SP | Credit Suisse to price 18-month ARES linked to basket of 10 stocks
|
| 2/20/2018 | SP | New Issue: Credit Suisse sells $95,023 call warrants linked to 20 stocks
|
| 2/16/2018 | SP | New Issue: Credit Suisse sells $149,992 call warrants linked to 20 stocks
|
| 2/16/2018 | SP | New Issue: Credit Suisse sells $83,500 call warrants linked to 20 stocks
|
| 2/15/2018 | SP | New Issue: Credit Suisse sells $149,951 call warrants linked to 20 stocks
|
| 2/15/2018 | SP | New Issue: Credit Suisse sells $175,000 return notes on basket of 20 stocks
|
| 2/8/2018 | SP | Credit Suisse to price 54-week call warrants linked to 20 stocks
|
| 2/8/2018 | SP | Credit Suisse to price return notes linked to basket of 20 stocks
|
| 2/5/2018 | SP | New Issue: JPMorgan sells $5.81 million return notes linked to basket of 20 stocks
|
| 2/5/2018 | SP | New Issue: Credit Suisse prices $425,971 call warrants linked to 20 stocks
|
| 1/31/2018 | SP | Credit Suisse to price return notes linked to basket of 20 stocks
|
| 1/24/2018 | SP | JPMorgan to price return notes linked to basket of 20 stocks
|
| 1/24/2018 | SP | Credit Suisse to price 54-week call warrants linked to 20 stocks
|
| 9/25/2017 | CV | Market Commentary: Air Transport, IAC/InterActive deals on tap; Marriott Vacations trades actively, better
|
| 8/23/2017 | CV | BioMarin greenshoe lifts 0.599% convertibles due 2024 to $495 million
|
| 8/11/2017 | CV | Market Commentary: Resource Capital eyed after new issue prices; Heritage deal quiet; Sutherland notes list
|
| 8/10/2017 | CV | Market Commentary: Resource Capital plans new issue; Heritage a no-show; BioMarin’s recent deal remains in play
|
| 8/10/2017 | CV | Market Commentary: Morning Commentary: Resource Capital plans new issue; BioMarin’s recent deal remains in play
|
| 8/9/2017 | CV | Market Commentary: Radius Health prices, dips below issue price; BioMarin busy; Priceline falters post-earnings
|
| 8/9/2017 | CV | Market Commentary: Morning Commentary: Radius Health prices, dips below issue price; BioMarin trading actively
|
| 8/8/2017 | CV | Market Commentary: BioMarin paper wanes in wake of new issue; Blackstone dips on add-on; Depomed tanks
|
| 8/8/2017 | CV | New Issue: BioMarin’s $450 million 0.599% seven-year notes come discounted at 98
|
| 8/8/2017 | CV | Market Commentary: Morning Commentary: BioMarin Pharmaceutical paper wanes in wake of new issue; Blackstone dips
|
| 8/7/2017 | CV | New Issue: BioMarin prices $450 million 0.599% convertible notes due 2024, up 40%
|
| 8/7/2017 | CV | Market Commentary: New issue pipeline builds with deals from BioMarin, Blackstone, Radius; Tesla improves
|
| 8/7/2017 | CV | BioMarin plans $450 million convertible notes due 2024 at discount; price talk 0.5999%, up 40%
|
| 12/2/2016 | BK | BioMarin gets $100 million two-year revolver with Bank of America
|
| 9/16/2016 | SP | New Issue: HSBC prices $3 million of AMPS linked to basket of 20 common stocks
|
| 9/8/2016 | SP | HSBC plans 15-month AMPS with cap linked to basket of 20 stocks
|
| 8/22/2016 | PP | Market Commentary: Biotech names eyed after Medivation takeout news; BioMarin convertibles add with shares
|
| 8/22/2016 | CV | Market Commentary: Biotech names eyed after Medivation takeout news; BioMarin convertibles add with shares
|
| 7/7/2016 | CV | Market Commentary: Weatherford expands as oil drops; BioMarin jumps on takeout chatter; older Tesla thrashed
|
| 7/7/2016 | PP | Market Commentary: Weatherford expands as oil drops; BioMarin jumps on takeout chatter; older Tesla thrashed
|
| 7/7/2016 | CV | Market Commentary: Morning Commentary: Light volume continues; BioMarin adds on swap on takeout chatter; EZCorp higher
|
| 6/17/2016 | PP | Market Commentary: Dynegy’s new 7% tangible units fly higher; BioMarin paper trends up on Sanofi takeover rumors
|
| 6/17/2016 | CV | Market Commentary: Dynegy’s new 7% tangible units fly higher; BioMarin paper trends up on Sanofi takeover rumors
|
| 6/17/2016 | CV | Market Commentary: Morning Commentary: Dynegy’s new tangible units fly higher; BioMarin trends up on Sanofi rumors
|
| 4/7/2016 | PP | Market Commentary: Healthcare flies higher as out-of-favor sector enjoys resurgence; DepoMed, BioMarin improve
|
| 4/7/2016 | CV | Market Commentary: Healthcare flies higher as out-of-favor sector enjoys resurgence; DepoMed, BioMarin improve
|
| 4/7/2016 | CV | Market Commentary: Morning Commentary: Health care continues to improve; BioMarin gains dollar neutral
|
| 3/7/2016 | SP | New Issue: Bank of America prices $2.2 million enhanced return notes on 10 stocks
|
| 2/29/2016 | SP | Bank of America to price enhanced return notes linked to 10 stocks
|
| 11/20/2015 | PP | Market Commentary: BioMarin bonds, stock drop as FDA criticizes drug; Mentor falls; SunEdison draining
|
| 11/20/2015 | CV | Market Commentary: BioMarin bonds, stock drop as FDA criticizes drug; Mentor falls; SunEdison draining
|
| 11/20/2015 | CV | Market Commentary: Morning Commentary: BioMarin bonds, stock drop as FDA criticizes drug; biotech wanes in sympathy
|
| 11/19/2015 | CV | Market Commentary: Chesapeake Energy gaps down; AMAG continues trajectory lower; Vodafone prices £600 million
|
| 10/6/2015 | CV | Market Commentary: Illumina convertibles down on swap in active trade after sales warning; primary quiet
|
| 9/25/2015 | CV | Market Commentary: Biotechnology names lower outright; AMAG Pharmaceuticals moves in line in active trade
|
| 9/25/2015 | CV | Market Commentary: Morning Commentary: AMAG Pharmaceuticals moves in line in continued active trade
|
| 9/21/2015 | PP | Market Commentary: Planned Weatherford looks cheap; BioMarin down in line; Volkswagen drops hard outright
|
| 9/21/2015 | CV | Market Commentary: Planned Weatherford looks cheap; BioMarin down in line; Volkswagen drops hard outright
|
| 7/28/2015 | SP | New Issue: JPMorgan prices $3.87 million 8.6% airbag autocallables linked to BioMarin
|
| 7/22/2015 | SP | JPMorgan plans 6.6%-8.6% airbag autocallables linked to BioMarin
|
| 7/15/2015 | CV | Market Commentary: Morning Commentary: Convertibles trade mostly in line, Micron slips back a little
|
| 6/18/2015 | PP | Market Commentary: Discounted Restoration Hardware remains below par; planned Ctrip.com seen modestly cheap
|
| 6/18/2015 | CV | Market Commentary: Discounted Restoration Hardware remains below par; planned Ctrip.com seen modestly cheap
|
| 6/17/2015 | SP | New Issue: UBS prices $178,000 trigger autocallable optimization securities linked to BioMarin Pharmaceutical
|
| 6/11/2015 | SP | New Issue: JPMorgan prices $3.26 million capped return enhanced notes on S&P 500
|
| 6/5/2015 | SP | New Issue: Credit Suisse prices $1 million 12.75% autocallable yield notes tied to BioMarin
|
| 6/4/2015 | CV | Market Commentary: Rate-sensitive convertible notes under pressure; Frontier Communications, Anadarko on tap
|
| 5/8/2015 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to BioMarin Pharmaceutical
|
| 4/27/2015 | SP | New Issue: JPMorgan prices $1 million autocallable reverse exchangeables linked to BioMarin
|
| 4/21/2015 | SP | New Issue: HSBC prices $3.03 million 7.8% airbag autocallables linked to BioMarin
|
| 4/15/2015 | SP | HSBC plans 6%-8% airbag autocallables tied to BioMarin Pharmaceutical
|
| 4/10/2015 | SP | New Issue: UBS prices $154,000 trigger autocallable optimization securities linked to BioMarin Pharmaceutical
|
| 3/30/2015 | PP | Market Commentary: Horizon Pharma jumps outright, adds on hedge; health-care bid remains strong; Intel active
|
| 3/30/2015 | CV | Market Commentary: Horizon Pharma jumps outright, adds on hedge; health-care bid remains strong; Intel active
|
| 3/27/2015 | PP | Market Commentary: BioMarin As gain on swap, BioMarin Bs in line amid takeout rumors; health care better bid
|
| 3/27/2015 | CV | Market Commentary: BioMarin As gain on swap, BioMarin Bs in line amid takeout rumors; health care better bid
|
| 3/27/2015 | CV | Market Commentary: Morning Commentary: BioMarin As outperforming, BioMarin Bs in line amid takeout rumors
|
| 2/19/2015 | PP | Market Commentary: Health care names weaker after Actavis launches large mandatory; Priceline slightly better
|
| 2/19/2015 | CV | Market Commentary: Health care names weaker after Actavis launches large mandatory; Priceline slightly better
|
| 2/18/2015 | SP | New Issue: RBC prices $1.2 million contingent absolute return autocallables linked to BioMarin
|
| 2/11/2015 | SP | RBC plans contingent absolute return autocallables linked to BioMarin
|
| 1/27/2015 | SP | New Issue: UBS prices $375,000 trigger phoenix autocallable optimization securities linked to BioMarin Pharmaceutical
|
| 1/21/2015 | SP | New Issue: JPMorgan prices $3.13 million trigger phoenix autocallables on BioMarin
|
| 1/13/2015 | PP | Market Commentary: Health care names better bid; Brocade extends dollar-neutral gain; Aegean Marine rises
|
| 1/13/2015 | CV | Market Commentary: Health care names better bid; Brocade extends dollar-neutral gain; Aegean Marine rises
|
| 1/13/2015 | SP | JPMorgan plans to price trigger phoenix autocallable notes linked to BioMarin Pharmaceutical
|
| 12/1/2014 | SP | New Issue: RBC prices $2.12 million buffered optimization notes tied to health care stocks
|
| 11/24/2014 | CV | Market Commentary: NXP Semiconductors launches and prices $1 billion deal; secondary market mostly quiet
|
| 11/24/2014 | CV | Market Commentary: Morning Commentary: NXP Semiconductors’ $1 billion offering in focus; secondary mostly quiet
|
| 10/24/2014 | PP | Market Commentary: Convertibles firm, but market pauses after volatile week; DryShips up after equity raise
|
| 10/24/2014 | CV | Market Commentary: Convertibles firm, but market pauses after volatile week; DryShips up after equity raise
|
| 10/24/2014 | CV | Market Commentary: Morning Commentary: Convertibles firm, but market pauses after volatile week; DryShips up
|
| 9/23/2014 | SP | New Issue: UBS prices $1.45 million airbag phoenix autocallable notes linked to BioMarin
|
| 9/17/2014 | SP | New Issue: UBS prices $200,000 trigger phoenix autocallable optimization securities linked to BioMarin Pharmaceutical
|
| 9/17/2014 | SP | UBS to price airbag phoenix autocallables linked to BioMarin
|
| 8/1/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to BioMarin Pharmaceutical
|
| 7/15/2014 | SP | New Issue: JPMorgan prices $2.87 million contingent absolute return autocallables tied to BioMarin
|
| 7/9/2014 | SP | JPMorgan plans contingent absolute return autocallables tied to BioMarin
|
| 6/25/2014 | SP | New Issue: UBS prices $238,000 contingent absolute return autocallables linked to BioMarin
|
| 6/16/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to BioMarin Pharmaceutical
|
| 6/12/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to BioMarin Pharmaceutical
|
| 6/11/2014 | SP | New Issue: UBS sells $2.85 million 9% airbag autocallable notes linked to BioMarin
|
| 6/4/2014 | SP | UBS to price 7.5%-9.5% airbag autocallables linked to BioMarin
|
| 5/30/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to BioMarin Pharmaceutical
|
| 5/2/2014 | CV | Market Commentary: Midday Commentary: Hologic active again; Fluidigm looks stronger; BioMarin shares down
|
| 5/2/2014 | CV | Market Commentary: BioMarin lower outright on earnings; Fluidigm stronger ahead of earnings; Hologic active
|
| 2/13/2014 | SP | New Issue: UBS prices $600,000 trigger phoenix autocallable optimization securities linked to BioMarin Pharmaceutical
|
| 1/31/2014 | SP | New Issue: UBS prices $1.41 million 10.3% airbag autocallables linked to BioMarin
|
| 1/27/2014 | SP | UBS plans 8.3%-10.3% airbag autocallables on BioMarin Pharmaceutical
|
| 12/31/2013 | CV | Outlook 2014: U.S. primary market looks stronger after 'turning a corner' in Q4; terms may cheapen
|
| 12/31/2013 | CV | Outlook 2014: U.S. secondary market poised for continued strength, but investors eye Fed taper
|
| 11/22/2013 | CV | Market Commentary: Midday Commentary: American Residential adds on debut; new Forestar, GAIN Capital quiet
|
| 11/22/2013 | CV | Market Commentary: Yahoo!'s new convertibles improve, in line from issue price; new American Residential adds
|
| 10/31/2013 | SP | New Issue: RBC prices $987,000 airbag yield optimization autocallables on BioMarin
|
| 10/24/2013 | CV | Market Commentary: New SanDisk edges up; existing SanDisk recovers; Covanta plunges outright, adds on hedge
|
| 10/23/2013 | SP | RBC plans 6.15%-8.15% airbag yield optimization notes tied to BioMarin
|
| 10/11/2013 | CV | Market Commentary: Ctrip.com surges on debut; Liberty Media up slightly; Seaspan cancels after stock drops
|
| 10/10/2013 | CV | BioMarin greenshoe exercise lifts convertibles deal to $750 million
|
| 10/10/2013 | CV | Market Commentary: Liberty, Ctrip.com deals look cheap; Ctrip adds in gray; BioMarin extends 'impressive' gains
|
| 10/9/2013 | CV | Market Commentary: Midday Commentary: New BioMarin tranches see bid surge, then pull back; new NQ Mobile quiet
|
| 10/9/2013 | CV | New Issue: BioMarin prices upsized $680 million of convertible bonds in two tranches
|
| 10/9/2013 | CV | Market Commentary: BioMarin tranches gain in active debut; new NQ slips outright; Tower sheds another point
|
| 10/8/2013 | CV | Market Commentary: Midday Commentary: New Navistar trades flat at discounted offer price; BioMarin in focus
|
| 10/8/2013 | CV | Market Commentary: New Navistar slips on debut; Tower Group drops again; planned BioMarin adds in the gray
|
| 10/8/2013 | CV | BioMarin revises terms on planned $600 million of convertibles
|
| 10/7/2013 | CV | BioMarin Pharmaceutical to price $600 million of convertible senior notes in two tranches
|
| 10/7/2013 | CV | Market Commentary: BioMarin Pharmaceutical launches $600 million deal; NQ Mobile, Seaspan, Navistar on tap
|
| 8/26/2013 | CVLM | BioMarin holders convert $31.5 million 1.875% notes for stock, cash
|
| 3/25/2013 | CVLM | BioMarin holders to exchange $75.8 million more 1.875% convertibles
|
| 3/18/2013 | CVLM | BioMarin issues shares, cash for $139.2 million of 1.875% convertibles
|
| 11/5/2012 | CV | Market Commentary: BioMarin up on drug data; Walter Investment pulls back; convertibles pause for elections
|
| 10/4/2012 | CV | Market Commentary: New Ares Capital flat after pricing at discount; WellPoint gains; NuVasive loses on hedge
|
| 7/3/2012 | CV | Market Commentary: Convertibles quiet ahead of holiday; Lincare, Theravance extend gains; U.S. Steel better
|
| 6/12/2012 | CV | Market Commentary: Navistar comes in on hedge; BioMarin expands; United Technologies plans $1 billion of units
|
| 6/11/2012 | CV | S&P affirms BioMarin
|
| 5/21/2012 | CV | Market Commentary: Kodak collapses on patent ruling; lesser credits weak; Newmont expands; SanDisk active
|
| 2/1/2012 | CV | Market Commentary: BioMarin climbs outright, premium slips; Suntech Power surges; China Medical plunges
|
| 9/12/2011 | CVLM | BioMarin issues shares, cash for $19.6 million of 2.5% convertibles
|
| 9/9/2011 | CV | Market Commentary: Convertibles under pressure as equities drop; Amerigroup, RadioShack lower; Dendreon flat
|
| 4/29/2011 | CV | S&P ups BioMarin convertibles
|
| 11/15/2010 | CVLM | BioMarin gives more stock, cash in exchange for converting 2.5% notes
|
| 11/9/2010 | CVLM | BioMarin issues shares, cash for $87 million of 2.5% convertibles
|
| 3/2/2010 | CV | Market Commentary: Newmont falls; Human Genome up on earnings, health care names bid higher; Annaly sells add-on
|
| 11/13/2009 | CV | Market Commentary: James River trades higher; Liberty Global prices deal; BioMarin slips on news; Ford gains
|
| 9/15/2009 | CV | Market Commentary: Smithfield expands on secondary offering; oil and gas names active; Best Buy flat to lower
|
| 7/31/2009 | SS | BioMarin shareholder Millenco reports 4.4% ownership interest
|
| 4/22/2009 | CVHY | S&P upgrades BioMarin
|
| 4/13/2009 | SS | Millenco buys, sells shares of BioMarin Pharmaceuticals for 5.6% interest
|
| 2/19/2009 | CV | Market Commentary: Financials extend losses; Wells Fargo preferreds sink to 400; Watson in focus after better earnings
|
| 2/10/2009 | CV | Market Commentary: Financials lower after bank plan; other convertibles hold up as equities slide; AMD steady
|
| 1/8/2009 | CV | Market Commentary: Convertibles trade mixed: Qwest gains with shares, but AMD sags; Enzon adds on extended tender
|
| 6/24/2008 | CVHY | S&P ups BioMarin outlook to positive
|
| 10/12/2007 | CV | Market Commentary: 'Sneak attack' from AMG; Morgans opens up; Ford drives on; Peabody, Biomarin lower
|
| 8/22/2007 | CV | Market Commentary: Countrywide continues recovery; Amgen, BioMarin nudge up; Ford edges down; market mayhem 'dying down'
|
| 5/31/2007 | SS | Market Commentary: Northwest climbs on return; A.G. Edwards surges on offer; Critical gains on approval; PDL slips on battle
|
| 5/8/2007 | CVHY | S&P ups BioMarin outlook to stable, rates convertibles CCC
|
| 4/23/2007 | CV | BioMarin greenshoe exercised, raising 1.875% convertibles to $324.875 million
|
| 4/18/2007 | CV | New Issue: BioMarin prices upsized $282.5 million 10-year convertibles to yield 1.875%, up 22.5%
|
| 4/18/2007 | CV | Market Commentary: BioMarin, Lawson start strong; Linear seen as rich; Delta Petroleum lacks borrow; BankUnited plans deal
|
| 4/17/2007 | CV | Market Commentary: Antigenics eases after surge; BioMarin, Lawson gain in gray; Linear, Delta Petroleum launch deals
|
| 4/16/2007 | CV | BioMarin talks $250 million 10-year convertibles at 1.625%-2.125%, up 17.5%-22.5%, to price Tuesday
|
| 4/16/2007 | CV | Market Commentary: Antigenics climbs on drug data; Electronic Data flat as rumors continue; BioMarin, Lawson launch deals
|
| 1/29/2007 | CV | BioMarin Pharmaceutical holders convert all $51.4 million of 3.5% notes ahead of redemption
|
| 12/22/2006 | CV | BioMarin Pharmaceutical calls $51.4 million of 3.5% convertibles
|
| 11/27/2006 | SS | Ford shares, preferreds skid; Nasdaq, LSE slip; biotechs lower; Raytheon drops; Ventas falls
|
| 11/2/2006 | BT | Merrill keeps BioMarin at buy
|
| 11/1/2006 | BT | BioMarin rated at buy by Merrill
|
| 11/1/2006 | BT | BioMarin reports net loss of $7 million for quarter, sales of Naglazyme, Aldurazyme up
|
| 9/25/2006 | BTCV | BioMarin issues 5.25 million shares, cash for $73.6 million 3.5% convertibles
|
| 9/20/2006 | BT | Merrill keeps BioMarin at buy
|
| 9/20/2006 | BT | BioMarin completes enrollment in 6R-BH4 hypertension study
|
| 9/12/2006 | BT | BioMarin, Serono release Phenoptin data in three clinical studies
|
| 9/12/2006 | BT | BioMarin keeps buy rating by Merrill
|
| 9/11/2006 | BT | BioMarin: Phenylase product development overcomes technical hurdles
|
| 9/6/2006 | BT | BioMarin preparing to begin clinical trials of 6R-BH4 for treatment of PAD, file NDA for Phenoptin
|
| 8/28/2006 | BT | BioMarin launches Orapred in United States through Alliant Pharmaceuticals
|
| 8/28/2006 | BT | Merrill keeps BioMarin at buy
|
| 8/3/2006 | BT | Merrill reiterates BioMarin at buy
|
| 7/10/2006 | BT | Merrill keeps BioMarin at buy
|
| 7/6/2006 | BT | BioMarin: first patient begins treatment in phase 2 trial of 6R-BH4 in hypertension
|
| 6/2/2006 | BT | Merrill Lynch maintains buy on BioMarin
|
| 6/1/2006 | BT | BioMarin, Alliant announce FDA approval of asthma medication Orapred ODT
|
| 5/19/2006 | BT | Merrill starts coverage of BioMarin at buy
|
| 5/5/2006 | BTCVDD | S&P assigns BioMarin Pharmaceuticals B-, notes CCC
|
| 4/4/2006 | CV | Market Commentary: Ciena's upsized $300 million deal up in gray market; American Equity higher; Symmetricom falls
|
| 3/30/2006 | CV | Market Commentary: BioMarin, Best Buy, Lamar Advertising gain; but Casual Male, Level 3, Interpublic are lower
|
| 3/28/2006 | BTCV | BioMarin greenshoes fully exercised, lifting convertibles to $172.5 million, stock to 10.35 million shares
|
| 3/24/2006 | BT | New Issue: BioMarin raises $117 million in follow-on of 9 million shares at $13 each versus $13.13 close
|
| 3/24/2006 | BT | Market Commentary: BioMarin shares, new bonds gain; Cephalon loses 13%; Idenix falls 28%; King slips; Encysive declines
|
| 3/24/2006 | CV | Market Commentary: Cephalon setback positive for hedged players; Lucent strengthens on merger talks; BioMarin starts strong
|
| 3/24/2006 | BTCV | New Issue: BioMarin prices upsized $150 million of seven-year convertibles at 2.5%, up 27.5%
|
| 3/23/2006 | BT | Market Commentary: BioMarin, King deals on deck; Cephalon poised to slide Friday; CombinatoRx off on PIPE deal
|
| 3/23/2006 | CV | Market Commentary: BioMarin new deal gets thumbs-up; YRC weaker on poor outlook; Cephalon fails to get FDA nod
|
| 3/21/2006 | BT | Market Commentary: Novavax, Nastech buck uptrend in flu names; NitroMed exec exits applauded; BioMarin off on deals
|
| 3/21/2006 | CV | Market Commentary: BioMarin comes in ahead of new issue; Casual Male seen as cheap; Vista delay could mean tech troubles
|
| 3/20/2006 | BTCV | BioMarin plans $125 million of 7-year convertibles talked at 2.5%-3%, up 22.5%-27.5%
|
| 3/20/2006 | BT | BioMarin Pharmaceutical to price 9 million share follow-on sale on Thursday
|
| 3/20/2006 | BT | Market Commentary: Boston Life Sciences' stock up as phase 3 trial ends early; BioMarin's stock dips on follow-on stock deal
|
| 3/20/2006 | CV | Market Commentary: Kerzner buyout hurts hedge investors; BioMarin plans new deal; Time Warner Telecom offer seen as cheap
|
| 3/20/2006 | BTCV | BioMarin Pharmaceutical files automatic shelf
|
| 3/17/2006 | CV | Market Commentary: General Motors falls in line with stock; Time Warner Telecom plans $200 million deal;
|
| 3/16/2006 | CV | Market Commentary: BioMarin stock hovers near strike price with call approaching; Kulicke and Soffa raises chip sector worries
|
| 3/16/2006 | BT | Market Commentary: Novavax, Nastech flu names on a tear; BioMarin higher on trial; Elite bobs, Titan slips on PIPEs
|
| 3/15/2006 | BT | BioMarin, Alliant enter licensing agreement for Orapred for asthma in children
|
| 3/15/2006 | BT | BioMarin, Serono say all primary, secondary endpoints met in Phenoptin study
|
| 2/24/2006 | BT | Market Commentary: Corautus, Cepheid deals emerge; BioMarin bounces; GCP gains on PIPEs deal; Par pounced on news
|
| 1/31/2006 | BT | Market Commentary: Nuvelo zooms after deal; SGX cuts guidance, prices at low end; Sepracor soars; BioMarin bounces
|
| 1/31/2006 | BT | BioMarin rated at peer perform by Thomas Weisel
|
| 1/30/2006 | BT | BioMarin receives marketing OK for Naglazyme in European Union
|
| 1/25/2006 | BT | BioMarin receives FDA Fast Track designation for Phenoptin for PKU
|
| 1/10/2006 | BT | BioMarin establishes commercial operations in Europe, names VP
|
| 12/19/2005 | BT | BioMarin amends loan, reducing interest rate by 25 bps
|
| 10/19/2005 | BT | BioMarin's Orapred ODT filing accepted by FDA
|
| 7/20/2005 | BT | Market Commentary: Accentia, Adams IPOs on deck as biotech index surges; BioMarin, Keryx bode well; Amgen rockets
|
| 7/14/2005 | BT | Market Commentary: Genentech active; CryoCor IPO trades up, sinks; Mylan prices tight, center; BioMarin off on follow-on
|
| 7/14/2005 | BT | New Issue: BioMarin sells 8.5 million shares at $7.05 each, discounted from Wednesday's close of $7.56
|
| 5/17/2005 | CV | Market Commentary: TOP Tankers deal re-sunk; Exide crashes; Calpine crumbles; Ford, GM, auto suppliers mixed
|
| 9/22/2004 | CV | Market Commentary: Interstate Bakeries trades at 85 on bankruptcy; Delta off; AMR warns after closing bell
|
| 8/31/2004 | CV | Market Commentary: Six Flags higher on Gates, Redskins owner play; IMC Global rises; Albertson's off
|
| 3/25/2004 | CV | Market Commentary: Chesapeake Energy lags other new paper at par; Grey Wolf talked at reoffer price of 99
|
| 9/22/2003 | CV | Market Commentary: Motorola gains with stock on CEO departure; BioMarin steady after drug canceled
|
| 6/18/2003 | CV | New Issue: BioMarin $125 million convertibles yield 3.5%, up 30%
|
| 6/18/2003 | CV | Market Commentary: CNet pulled, other new deals sweetened; Reliant upsizes as buyers reach for a fat coupon
|
| 6/17/2003 | CV | Biomarin $125 million convertibles yield 3.5%, up 30%
|
| 6/17/2003 | CV | Market Commentary: New deal parade marches on; Lattice reoffered at 98, still dives; secondary thin, lower
|
| 6/16/2003 | CV | BioMarin $125 million convertible talked to yield 3.0-3.5%, up 30-35%
|
| 6/16/2003 | CV | Market Commentary: ICOS, Lattice at bat; buzz puts Nextel Partners eyeing another convert after new junk offering
|
